Why is Immatics stock climbing today?

Imatics stock experienced a significant increase of nearly 4.7% in pre-market trading, reaching a price of $9.10. The company disclosed plans to sell 12,945,916 shares and 4,315,304 pre-funded warrants at $8.69 per share each, totaling a $150 million underwritten public offering. This announcement was bolstered by a reaffirmation of its Buy rating from Goldman Sachs, an investment bank.

The endorsement came in the early pre-market hours, shortly after Immatics released its second-quarter 2026 interim financial results, providing investors with positive signals ahead of the opening bell. The company's strong performance and recent achievements have contributed to a strong consensus among analysts, with a majority rating it as a Strong Buy and assigning average price targets ranging from $17 to $19, more than double the current pre-market price.

Additionally, the broader NASDAQ Composite is also on the rise, providing a supportive macro tailwind for growth-oriented biotech stocks. Together, these factors – the share offering, recent earnings beat, clinical milestones, and Goldman Sachs' Buy reaffirmation – have created an attractive pre-market setup for Immatics, despite the stock trading below its 52-week high of $12.41.

Analysts broadly expect significant upside for the company as it progresses toward its first potential commercial product.